Loading…
Employees: 350
Size Tauns Laboratories (197A.T) is a Japan Health Care company (Medical Specialties) with a market value of $322M, the 1322nd largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥476 on 6 Nov 2026.
Performance Over six months the shares fell 2.3%, against -10.4% for the median peer and +1.8% for the Japan market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 22.9% over the last twelve months (peer median +7.6%); the operating margin is 29.2% (peer median 4.9%).
Valuation It trades at 15.5× forward earnings against a peer median of 15.8× (5th cheapest of 9).
Capital Return on invested capital runs 2.9 points above its cost of capital (5.0% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥14.4B | ¥14.4B | ¥18.6B | ¥18.4B | ¥15.7B |
| Revenue growth | — | -23% | +1% | +18% | — |
| Gross profit | ¥8.82B | ¥8.29B | ¥12.3B | ¥12.1B | ¥8.79B |
| EBITDA | ¥5.33B | ¥5.33B | ¥8.98B | ¥8.71B | ¥5.61B |
| Net income | ¥5.50B | ¥5.50B | ¥6.32B | ¥5.77B | ¥3.03B |
| Free cash flow | n/a | -¥6.61B | ¥2.14B | ¥6.18B | -¥4.25B |
| Capital expenditure | n/a | ¥4.02B | ¥5.12B | ¥3.96B | ¥1.17B |
| Total debt | ¥21.3B | ¥21.3B | ¥14.4B | ¥9.54B | ¥6.47B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 197A.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.5% | -5.6% | 10th lowest of 21 |
| 6-month return | -2.3% | -10.4% | 8th highest of 21 |
| Distance from 52-week high | -17.5% | -36.3% | 5th highest of 21 |
| Revenue growth (TTM) | -22.9% | +7.6% | lowest of 21 |
| Operating margin | 29.2% | 4.9% | 3rd highest of 21 |
| Forward P/E | 15.5× | 15.8× | 5th cheapest of 9 |
| ROIC minus cost of capital | +2.9 pp | -3.9 pp | 8th highest of 19 |
| EV / EBITDA | 12.9× | 10.2× | 5th most expensive of 12 |
| Net debt / EBITDA | 3.3× | -2.4× | 3rd most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 15.5× | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | n/a | 6.1% | +16.4% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 27.8× | 4.3% | +56.8% |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 10.7× | -9.0% | +20.2% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | n/a | n/a | n/a |
| Improve Medical Instruments 300030.SZ | China | $320M | -17% | -2% | 4% | n/a | 26.0% | -11.9% |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | n/a | 22.5% | -10.9% |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | n/a | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 335.5× | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 16.4× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | n/a | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | n/a | 31.9% | -4.5% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 15.0× | -19.8% | -28.5% |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | n/a | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 3.9× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | n/a | n/a | n/a |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 15.2× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| i3system 214430.KS | South Korea | $287M | -48% | +8% | 13% | n/a | n/a | n/a |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | n/a | -13.2% | +36.8% |